BIVICTRIX THERAPEUTICS
Biotech focused on developing novel, highly-selective, bispecific ADCs to target unmet need in blood cancer.
BIVICTRIX THERAPEUTICS
Social Links:
Industry:
Biotechnology Life Science Pharmaceutical Therapeutics
Founded:
2016-01-01
Address:
Alderley Edge, Cheshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.bivictrix.com
Total Employee:
1+
Status:
Active
Total Funding:
0
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt WordPress Font Awesome Wordpress Plugins Nginx
Similar Organizations
Imvax
Imvax is a biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies.
Current Employees Featured
Founder
Investors List
Alderley Park Ventures
Alderley Park Ventures investment in Seed Round - BiVictriX Therapeutics
Development Bank of Wales
Development Bank of Wales investment in Seed Round - BiVictriX Therapeutics
Official Site Inspections
http://www.bivictrix.com Semrush global rank: 5.48 M Semrush visits lastest month: 1.56 K
- Host name: 204.33.214.35.bc.googleusercontent.com
- IP address: 35.214.33.204
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "BiVictriX Therapeutics"
Home - Bivictrix
Welcome to BiVictriX Cancer is a notoriously difficult disease to treat as cancer cells can effectively ‘hide’ amongst the healthy cells within the body. To generate truly effective cancer therapies, we must unveil the cancer cells making them …See details»
About Us - Bivictrix
BiVictriX is a rapidly emerging biotechnology company applying a novel approach to develop safer, more effective cancer therapies. We have developed Bi-Cygni® therapeutics, which are …See details»
BiVictriX Therapeutics - Crunchbase Company Profile & Funding
Organization. BiVictriX Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Biotech is a biotechnology company …See details»
BiVictriX Therapeutics - VentureRadar
" Established in 2016, BiVictriX Therapeutics Ltd is a North-West based biotech focused on developing and licensing novel, highly-selective, bispecific Antibody Drug Conjugates (ADCs) …See details»
BiVictriX Therapeutics - Funding, Financials, Valuation & Investors
BiVictriX Therapeutics is registered under the ticker LSE:BVX . Their stock opened with £0.20 in its Aug 11, 2021 IPO. BiVictriX Therapeutics is funded by 4 investors. Innovate UK and O2h …See details»
BiVictriX Therapeutics Ltd Company Overview, Contact Details ...
BiVictriX's Bi-Cygni therapeutics are engineered to selectively target unique cancer-specific twin antigen fingerprints, which are largely absent from healthy cells. The Bi-Cygni approach links …See details»
BIVICTRIX LIMITED Company Profile - Dun & Bradstreet
Bivictrix limited. d&b business directory home / business directory / professional, scientific, and technical services / scientific research and development services / united kingdom / …See details»
BiVictriX Therapeutics - Contacts, Employees, Board Members, …
Organization. BiVictriX Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 2. Contacts 7. …See details»
BiVictriX Therapeutics - The Org
BiVictriX is a drug discovery and development company. Their services include oncology, haematological malignancies, bispecific ADC therapeutics, biotherapeutics, immunotherapy, …See details»
BiVicTrix Therapeutics PLC - JP Jenkins
Feb 15, 2016 BiVictriX Therapeutics Ltd (“BVX”) is an emerging biotechnology company leveraging clinical experience and its proprietary discovery engine to advance a new class of …See details»
BiVictriX Therapeutics - Overview, News & Similar companies
Oct 3, 2023 Who is BiVictriX Therapeutics. Established in 2016, BiVictriX Therapeutics Ltd is a North West based Biotech focused on developing novel, highly-selective, bispecific ADCs to …See details»
Company BiVictriX Therapeutics plc - MarketScreener.com
Dec 31, 2015 BiVictriX Therapeutics plc is a drug discovery and development company. The Company is focused on leveraging clinical experience to develop highly selective cancer …See details»
BiVictriX Therapeutics - Craft
BiVictriX Therapeutics Summary. Company Summary. Overview. BiVictriX Therapeutics is an oncology-focused biotech company. It works on the generation of Antibody Drug Conjugates …See details»
Science - Bivictrix
BiVictriX is building a novel pipeline of first-in-class therapeutics that have superior cancer selectivity. By significantly reducing harmful side-effects, we aim to vastly improve the safe …See details»
BIVICTRIX LIMITED overview - Find and update company …
More for BIVICTRIX LIMITED (10005270) Registered office address Mereside Alderley Park, Alderley Edge, Macclesfield, England, England, SK10 4TG . Company status Active Company …See details»
BiVictriX raises £7m and lists on the AIM Market - Acceleris
The founder behind the Bi-Cygni® concept is Tiffany Thorn, CEO of BiVictriX. Leveraging her past experiences as a clinician involved in diagnosing blood cancers, Tiffany brought this innovative …See details»
BiVictriX - o2h ventures
BiVictriX Therapeutics is an emerging biotechnology company applying a novel approach to develop next-generation cancer therapies using insights derived from frontline clinical …See details»
BiVictriX announces expansion of its therapeutic pipeline with two ...
Jun 30, 2024 BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived …See details»
BiVictriX Full Year Results
Mar 29, 2023 Tiffany Thorn, Chief Executive Officer of BiVictriX, commented: "We have made signficant progress over the past year with our lead programme, BVX001, advancing this …See details»
BiVictriX and Abzena Enter Collaboration - FT.com
Nov 18, 2021 BiVictriX has identified a diverse panel of novel cancer-specific "twin antigens", across a broad range of cancer indications including Diffuse Large B Cell Lymphoma, Acute …See details»